NF1 and plexiform neurofibroma: Notably, the recently published ReNeu trial found that children with NF-1 associated inoperable symptomatic plexiform neurofibromas treated with intermittent dosing of Mirdametinib (3 weeks on/1 week off) met the primary efficacy endpoint, with ORR of 52% (46).